BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference
BioSig Technologies, Inc. (NASDAQ: BSGM) announced that Kenneth L. Londoner, Chairman and CEO, will present at the Sidoti Winter 2021 Investor Conference on January 13, 2021, at 2:30 PM ET. The presentation will cover company highlights and achievements, including over 410 patient procedures with the PURE EP™ System conducted by 32 electrophysiologists in seven U.S. clinical sites. Interested parties can register for the presentation and one-on-one meetings through provided links.
- None.
- None.
Westport, CT, Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the Sidoti Winter 2021 Investor Conference on Wednesday, January 13, 2021 at 2:30 PM ET.
During the presentation, Mr. Londoner will provide an overview of the Company and business highlights. To date, more than 410 patient procedures have been conducted with the PURE EP™ System by more than 32 electrophysiologists across seven different clinical sites in the United States.
To access the presentation, please register here.
Management will also be available for 1x1s. Interested parties may register for those here: Sidoti January Conference Investor Registration
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What is the date and time of BioSig Technologies' presentation at the Sidoti Winter 2021 Investor Conference?
How many patient procedures have been conducted using the PURE EP™ System?
Who is presenting for BioSig Technologies at the investor conference?
How many electrophysiologists are using the PURE EP™ System?
Where can I register to attend BioSig Technologies' conference presentation?
